Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Birmingham

Beverly Hills

Burbank

La Jolla

Los Angeles

Pomona

San Diego

New Haven

Fort Myers

Jacksonville

Orange City

Atlanta

Augusta

Chicago

Iowa City

Louisville

New Orleans

Baltimore

Ann Arbor

Southfield

St Louis

Hackensack

Morristown

Somerville

New York

Durham

Hickory

Canton

Cleveland

Portland

Danville

Hershey

Charleston

Nashville

Houston

San Antonio

Salt Lake City

Burlington